Tag: PALISADE

AR101

Aimmune Therapeutics Presents New AR101 Data Including Demonstrated Reduction in Accidental...

AR101-Treated Patients Who Completed PALISADE Had 95% Increased Probability of Tolerating Any Dose of Peanut Protein in Exit Challenge Compared to Placebo.
AR101

Aimmune to Submit FDA Application for Peanut OIT Candidate by End...

If approved, AR101 could be offered as the first FDA approved OIT therapy for peanut allergy.
Paliforzia (AR101)

Results of Phase III Trial of Aimmune’s Peanut OIT Therapy

After one year, 3/4 of patients ages 4-17 who received the therapy were able to consume a minimum of 300mg of peanut. Results for adults were less clear.

Connect with Us

39,582FansLike
863FollowersFollow
2,737FollowersFollow
5,564FollowersFollow
41SubscribersSubscribe